Harris & Harris Group, Inc.®

Transformative Companies Enabled by Nanotechnology
SAFE HARBOR STATEMENT

This presentation may contain statements of a forward-looking nature relating to future events. Statements contained in this presentation that are forward-looking statements are intended to be made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions. These statements reflect the Company’s current beliefs, and a number of important factors could cause actual results to differ materially from those expressed herein.

Please see the Company’s Annual Report on Form 10-K, as well as subsequent filings, filed with the Securities and Exchange Commission for a more detailed discussion of the risks and uncertainties associated with the Company’s business, including but not limited to the risks and uncertainties associated with venture capital investing and other significant factors that could affect the Company’s actual results. Except as otherwise required by Federal securities laws, Harris & Harris Group, Inc. undertakes no obligation to update or revise these forward-looking statements to reflect new events or uncertainties.
INVESTING EXCLUSIVELY IN NANOTECHNOLOGY SINCE 2002

Contour Energy Systems
ABS Materials
Solazyme
Nanosys
Laser Light Engines
Bridgelux
Ensemble Discovery
Cobalt Biofuels
D-Wave
Nantero
SiOnyx
BioVex
Cambrios
Adesto Technologies
Metabolon
Kovio
Mersana
Molecular Imprints
## We Have a Pipeline of Portfolio Companies

<table>
<thead>
<tr>
<th></th>
<th>Cleantech</th>
<th>Healthcare</th>
<th>Electronics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Early Stage</strong></td>
<td>Laser Light Engines</td>
<td>Ancora</td>
<td>Adesto</td>
</tr>
<tr>
<td></td>
<td>Produced Water Absorbents</td>
<td>Enumeral</td>
<td>SiOnyx</td>
</tr>
<tr>
<td></td>
<td>Nextreme</td>
<td></td>
<td>D-Wave Systems</td>
</tr>
<tr>
<td></td>
<td>Ultora</td>
<td></td>
<td>Nantero</td>
</tr>
<tr>
<td><strong>Mid Stage</strong></td>
<td>Cobalt Contour Energy</td>
<td>Mersana</td>
<td>Cambrios</td>
</tr>
<tr>
<td></td>
<td>ABSMaterials</td>
<td>Ensemble</td>
<td>Kovio</td>
</tr>
<tr>
<td><strong>Late Stage</strong></td>
<td><strong>Solazyme (NASDAQ:SZYM)</strong></td>
<td>Metabolon</td>
<td>Xradia</td>
</tr>
<tr>
<td></td>
<td>Bridgelux</td>
<td></td>
<td>NeoPhotonics (NYSE:NPTN)</td>
</tr>
<tr>
<td></td>
<td>Innovalight&lt;sup&gt;(1)&lt;/sup&gt;</td>
<td></td>
<td>Molecular Imprints</td>
</tr>
<tr>
<td></td>
<td>Nanosys</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Realized Positive Exits</strong></td>
<td>Siluria</td>
<td>NanoGram Devices</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>BioVex&lt;sup&gt;(2)&lt;/sup&gt;</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Portfolio companies and stage classifications as of June 30, 2011. Table does not include portfolio companies valued at $0 as of June 30, 2011.

<sup>(1)</sup> Innovalight was acquired by DuPont on July 21, 2011

<sup>(2)</sup> A portion of the potential amount we will receive from the sale of BioVex remains unrealized as of June 30, 2011.
Note: All numbers are as of March 31, 2011.
WE WERE EARLY INVESTORS IN TODAY’S GROWTH MARKETS

Healthcare

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010

Cancer Therapeutics – Biologics

BioVex (Acq. By Amgen)

Disease free at 4 years

Tumor cell  Virus replicates  Tumor cell ruptures and dies (cell lysis)

Oncolytic virus

Healthy cell  Virus does not replicate  Healthy cell undamaged

Virus spreads & promotes immune response to distant tumors
TRENDS IN NANO-MEDICINE

MEDICINE

- Materials Science
  - Orthobiologics
  - Wound Care

- Chemistry
  - Antibody Engineering
  - New Classes of Therapeutics

- Electronics
  - Diagnostics Tools
  - Healthcare Sensors

- Physics
  - Imaging
  - Biological NanoMechanics
TRENDS IN NANO MEDICINE

1. **3D Biology**
   - Limitations of 2D models for drug development.

2. **Molecular Engineering**
   - Engineering proteins and small molecules to enable new classes of compounds.

3. **Personalized Medicine**
   - Trends in molecular diagnostics.

4. **Cellular Therapy**
   - Trends in stem cell therapy.
Our Healthcare Portfolio

Acquired by Amgen: up to $1 billion